重组抗HIV V3环聚糖单克隆抗体(PGT121),人IgG1 Lambda | Syd Labs PA007172

重组抗HIV V3环聚糖单克隆抗体(PGT121),人IgG1 Lambda Syd Labs PA007172

重组抗HIV V3环聚糖单克隆抗体(PGT121),人IgG1 Lambda | Syd Labs PA007172

In stock

一键复制

Syd Labs生产的体内实验级重组抗HIV-1广谱中和单克隆抗体,由国际经典PGT121克隆可变区融合人IgG1 Lambda恒定区构成,经哺乳动物细胞表达纯化。该抗体靶向HIV-1包膜糖蛋白gp120 V3环基部高度保守的N332高甘露糖聚糖表位,通过同时识别N332聚糖和V3环保守GDIR蛋白基序发挥中和作用,对约70%全球HIV-1流行株具有极强的中和活性(多数敏感株IC50达pM级别),同时具有强效ADCC活性。产品内毒素水平<1EU/mg,纯度>95%,严格符合体内实验质控标准,可用于HIV被动免疫预防研究、SHIV攻毒保护实验、病毒中和实验、Env结构生物学研究等体内外应用。

产品参数

货号 PA007172
产品名称重组抗HIV V3环聚糖单克隆抗体(PGT121),人IgG1 Lambda | Syd Labs PA007172
英文名 In Vivo Grade Recombinant Anti-HIV V3 Loop Glycan Monoclonal Antibody (Clone PGT121), Human IgG1 Lambda
供货商名称 Syd Labs, Inc.
品牌名 Syd Labs
别称 抗HIV V3-glycan抗体、PGT121广谱中和抗体、抗HIV N332聚糖bNAb、V3环靶向中和抗体
概述 靶向HIV-1 gp120 V3环基部N332高甘露糖聚糖表位的强效广谱中和抗体,克隆PGT121,人IgG1 Lambda型,pM级中和活性,体内实验级质控,适用于体内外HIV研究
克隆号 PGT121
同种型 人IgG1 Lambda
特异性 同时识别gp120上N332位点高甘露糖聚糖和V3环保守GDIR蛋白基序,形成聚糖-蛋白复合表位识别,不识别未糖基化蛋白,对N332糖基化突变株中和活性显著下降
纯化 蛋白A亲和层析纯化
抗体形式 0.2μm过滤除菌的1×PBS溶液(pH7.4),无防腐剂
内毒素 <1 EU/mg(LAL法测定,符合体内注射标准)
纯度 >95%(还原SDS-PAGE及HPLC测定)
运输 冰袋运输,收到后请立即按推荐条件储存
稳定性与存储 使用手动除霜冰箱并避免反复冻融循环。2-8℃自收到之日起可保存1个月;-20℃至-70℃自收到之日起可保存12个月,建议分装保存
注意事项 PA007172 Syd Labs:该抗体识别糖基化依赖的构象表位,实验中避免使用去糖基化酶处理抗原,避免变性条件;N332位点突变毒株会产生耐药,实验前需验证毒株N332糖基化状态;体内注射前请用无菌PBS稀释,避免污染。批量订购可享更低价格。
产品咨询 Syd Labs在国内只通过代理商销售其产品,不做直销。终端用户咨询价格请联系Syd Labs中国代理商。
关于Syd Labs产品如果有任何技术或其它问题,欢迎随时联系Syd Labs国内市场推广合作伙伴:武汉多找找科技有限公司,企业微信:duozhaozhao2024 联系电话:18162581039(龙经理)
应用详情 ELISA、Western Blot、流式细胞术(FCM)、病毒中和实验、SHIV/HIV体内攻毒保护实验、被动免疫预防研究、Env糖基化分析、结构生物学研究、ADCC功能实验、各类体内外功能实验

文献

重组抗HIV V3环聚糖单克隆抗体(克隆号:PGT121)人IgG1 Lambda,体内实验级(In Vivo Grade Recombinant Anti-HIV V3 Loop Glycan Monoclonal Antibody (Clone PGT121), Human IgG1 Lambda)

重组抗HIV V3环聚糖单克隆抗体背景知识:

1. PGT121克隆来源与核心特性‌
PGT121是2011年由IAVI和Scripps研究所团队从非洲HIV感染者外周血记忆B细胞中分离得到的V3-聚糖靶向广谱中和抗体,属于PGT121/128抗体谱系,是最早报道的pM级超高亲和力抗HIV bNAb之一。该抗体拥有较长的CDR H3环,可穿透HIV Env表面的聚糖盾结合V3环基部,其序列和晶体结构已被解析,是HIV抗体领域引用量最高、应用最广泛的克隆之一。

‌2. V3环N332聚糖靶点的生物学意义‌
HIV-1 gp120的V3环是病毒结合共受体CCR5/CXCR4的关键区域,其中N332位点是Env上最保守的N-糖基化位点之一,在超过90%的全球流行株中存在。该位点周围被多个高甘露糖聚糖包裹形成聚糖盾,PGT121可同时结合N332聚糖和V3环保守蛋白骨架,这种“聚糖-蛋白”双重识别模式使其兼具高特异性和极高亲和力,同时能有效抵抗病毒常见的逃逸突变。

‌3. 临床与研究应用价值‌
PGT121在非人灵长类SHIV攻毒模型中显示出目前已知最强的体内保护效力,单次5mg/kg剂量注射即可提供超过3个月的完全保护,其LS突变长半衰期版本(PGT121-LS)单次注射可提供6个月以上保护,目前PGT121及其长效版本已进入HIV预防和治疗的多项I/II期临床研究。同时,PGT121也被广泛用于HIV Env糖基化分析、疫苗免疫原评估、病毒逃逸机制研究、双特异性抗体开发等基础和转化研究领域。

‌4. 体内实验级质控标准‌
PA007172严格按照体内注射级标准生产:无血清化学成分确定培养基表达,无动物源成分,内毒素<1EU/mg,蛋白聚集率<1%,经0.2μm无菌过滤,无支原体、外源病毒污染,可直接用于小鼠、恒河猴等动物模型的被动免疫、攻毒保护等体内实验。

重组抗HIV V3环聚糖单克隆抗体部分参考文献:

1.Broad neutralization coverage of HIV by multiple highly potent antibodies
Laura M Walker,et al.Nature. 2011.PMCID: PMC3393126
“Broadly neutralizing antibodies (bNAbs) to HIV-1 provide templates for vaccine design and are candidates for prophylaxis and therapy. Here we isolated and characterized a new panel of antibodies from HIV-infected donors that show exceptional neutralization potency and breadth. PGT121 in particular neutralized 70% of global HIV-1 isolates with geometric mean IC50 of 0.03 μg/ml, making it one of the most potent anti-HIV antibodies identified to date. PGT121 and related antibodies target a glycan-dependent epitope in the V3 loop region of gp120, centered on the N332 glycosylation site, and demonstrate that potent, broad neutralization can be achieved by recognition of glycan-protein composite epitopes.”

2.Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V3-directed antibodies
Marie Pancera,et al.Nat Struct Mol Biol. 2013.PMCID: PMC3766620
“V3-directed antibodies such as PGT121, PGT128 and 2G12 recognize HIV-1 Env through glycan-dependent interactions and mediate potent broad neutralization. Here we report crystal structures of PGT121 and PGT128 Fabs in complex with gp120 and high-mannose glycans. We find that PGT121 uses a long CDR H3 loop to penetrate the glycan shield, forming critical contacts with both the N332 high-mannose glycan and conserved GDIR motif residues in the V3 loop base. The structures reveal how these antibodies accommodate glycan heterogeneity while maintaining high affinity and broad recognition, providing a template for design of immunogens to elicit V3-glycan directed bNAbs by vaccination.”

3.Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo
Bettina Moldt,et al.Proc Natl Acad Sci U S A. 2012.PMCID: PMC3519302
“Broadly neutralizing antibodies are promising candidates for HIV prevention, but the relationship between in vitro neutralization potency and in vivo protection has not been fully defined. We evaluated the protective efficacy of PGT121 against repeated mucosal SHIV challenges in rhesus macaques. A single intravenous dose of PGT121 at 5 mg/kg provided complete protection against all intrarectal challenges for up to 23 weeks, with protection observed at serum concentrations as low as 0.05 μg/ml, consistent with its extraordinary in vitro potency. No breakthrough infections occurred in animals with detectable PGT121 serum levels, demonstrating that high in vitro neutralization potency directly translates to robust in vivo protection.”

4.A single injection of PGT121-LS protects macaques against repeated SHIV challenges for 6 months
Rajeev Gautam,et al.Nat Commun. 2018.PMCID: PMC6145800
“Long-acting broadly neutralizing antibodies are a promising approach to reduce HIV transmission frequency. We engineered PGT121 with LS (M428L/N434S) Fc mutations to extend its serum half-life approximately 3-fold. A single intramuscular injection of PGT121-LS at 5 mg/kg provided complete protection against repeated weekly intrarectal SHIV challenges in rhesus macaques for 6 months, with 50% protective serum concentrations estimated at <0.03 μg/ml. The excellent long-term protection and favorable safety profile of PGT121-LS support its clinical development as a long-acting HIV prevention agent, which is currently being evaluated in human clinical trials.”

5.Recent progress in broadly neutralizing antibodies to HIV
Devin Sok, Dennis R Burton.Nat Immunol. 2018.PMCID: PMC6202283
“Over the past decade, the field has isolated a large number of highly potent and broad HIV-neutralizing antibodies targeting multiple conserved epitopes on the Env trimer. V3-glycan directed antibodies such as PGT121 stand out for their exceptional potency, which is among the highest of all known anti-HIV antibodies, and their ability to mediate Fc-dependent effector functions including ADCC that contribute to clearance of infected cells. These antibodies have advanced into clinical trials for both HIV prevention and therapy, and their structures have guided next-generation vaccine design efforts aimed at eliciting similar protective antibody responses by vaccination.”